The use of bolus insulin and advancing insulin therapy in type 2 diabetes

Current Diabetes Reports

Volumn 4, Issue 5, 2004, Pages 352-357

  Karl, Diane M ^a  

^a Endocrine Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA; TROGLITAZONE;

BODY WEIGHT DISORDER; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; FOOD DRUG INTERACTION; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; WEIGHT GAIN;

EID: 8344235966     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0037-1     Document Type: Review

References (27)

1. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
2. Rosenbloom AL, Joe JR, Young RS, Winter WE: Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999, 22: 45-354.
3. Hillier TA, Pedula KL: Complications in young adults with early-onset type 2 diabetes. Diabetes Care 2003, 26: 999-3005.
4. Mudaliar SP, Lindberg FA, Joyce M, et al.: Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22:1501-1506.
5. Homko C, Deluzzio A, Jimenez C, et al.: Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003, 26:2027-2031.
6. Roach P, Yue L, Arena V: Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation: Humalog Mix25 Study Group. Diabetes Care 1999, 22:1258-1261.
7. Weyer C, Heise T, Heinemann L: Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997, 20: 612-1614.
8. Yki-Jarvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
9. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial. Diabetes Care 2003, 26:3080-3086.
10. Feinglos MN, Thacker CH, English J, et al.: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997, 20:1539-1542.
11. Landstedt-Hallin L, Adamson U, Arner P, et al.: Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995, 18:1183-1186.
12. Bastyr EJ, Stuart C, Brodows RG, et al.: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000, 23: 236-1241.
13. Henry RR, Gumbiner B, Ditzler T, et al.: Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial. Diabetes Care 1993, 16: 1-31.
14. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al.: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:1426-1433.
15. Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21: 052-1057.
16. Wulffele MG, Kooy A, Lehert P, et al.: Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 25:2133-2140.
17. Strowig SM, Aviles-Santa ML, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002, 25:1691-1698.
18. Strowig SM, Aviles-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004, 27:1577-1583.
19. Hermansen K, Colombo M, Storgaard H, et al.: Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002, 25: 83-888.
20. Bretzel RG, Arnolds S, Medding J, Linn T: A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004, 27:1023-1027.
21. Raskin P, Bode BW, Marks J, et al.: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003, 26: 598-2603.
22. Cefalu WT, Skyler JS, Kourides IA, et al.: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001, 134:203-207.
23. Kim D, Mudaliar S, Chinnapongse S, et al.: Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003, 26:2842-2847.
24. Thompson RG, Gottlieb A, Organ K, et al.: Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 1997, 14:547-555.
25. Fineman M, Bicsak TA, Shen LZ, et al.: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26:2370-2377.
26. Juhl CB, Hollingdal M, Sturis J, et al.: Bedtime administration of NN2211, a long-acting GLP-1 derivative substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51:424-429.
27. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004, 27:17-20.